Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

OBJECTIVES: To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). METHODS: Demographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two...

Descripción completa

Detalles Bibliográficos
Autores principales: Machado, Pedro M, Schäfer, Martin, Mahil, Satveer K, Liew, Jean, Gossec, Laure, Dand, Nick, Pfeil, Alexander, Strangfeld, Anja, Regierer, Anne Constanze, Fautrel, Bruno, Alonso, Carla Gimena, Saad, Carla G S, Griffiths, Christopher E M, Lomater, Claudia, Miceli-Richard, Corinne, Wendling, Daniel, Alpizar Rodriguez, Deshire, Wiek, Dieter, Mateus, Elsa F, Sirotich, Emily, Soriano, Enrique R, Ribeiro, Francinne Machado, Omura, Felipe, Rajão Martins, Frederico, Santos, Helena, Dau, Jonathan, Barker, Jonathan N, Hausmann, Jonathan, Hyrich, Kimme L, Gensler, Lianne, Silva, Ligia, Jacobsohn, Lindsay, Carmona, Loreto, Pinheiro, Marcelo M, Zelaya, Marcos David, Severina, María de los Ángeles, Yates, Mark, Dubreuil, Maureen, Gore-Massy, Monique, Romeo, Nicoletta, Haroon, Nigil, Sufka, Paul, Grainger, Rebecca, Hasseli, Rebecca, Lawson-Tovey, Saskia, Bhana, Suleman, Pham, Thao, Olofsson, Tor, Bautista-Molano, Wilson, Wallace, Zachary S, Yiu, Zenas Z N, Yazdany, Jinoos, Robinson, Philip C, Smith, Catherine H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176347/
https://www.ncbi.nlm.nih.gov/pubmed/36787993
http://dx.doi.org/10.1136/ard-2022-223499
Descripción
Sumario:OBJECTIVES: To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). METHODS: Demographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression. RESULTS: Of 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25–2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39–2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42–0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19. CONCLUSION: Older age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics.

Ejemplares similares